We also discovered that paclitaxel, a clinically approved anticancer drug, can be utilized to treat HCC patients with mutant TP53 or wild-type CTNNB1 genes, providing a precision treatment option for the future. The gene discussed is TP53; the disease is hepatocellular carcinoma.